545 related articles for article (PubMed ID: 26684470)
21. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
22. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
23. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.
Ohzawa H; Sakatani T; Niki T; Yasuda Y; Hozumi Y
Breast Cancer; 2014 Sep; 21(5):563-70. PubMed ID: 23108629
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
25. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
[TBL] [Abstract][Full Text] [Related]
27. Triple-Negative Breast Cancer Subclassified by Immunohistochemistry: Correlation with Clinical and Pathological Outcomes in Patients Receiving Neoadjuvant Chemotherapy.
Paula B; Crocamo S; de Sousa CAM; Valverde P; Rezende F; Abdelhay E
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892013
[TBL] [Abstract][Full Text] [Related]
28. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
[TBL] [Abstract][Full Text] [Related]
29. The accuracy of MRI in detecting pathological complete response following neoadjuvant chemotherapy in different breast cancer subtypes.
Kuzmova M; Cullinane C; Rutherford C; McCartan D; Rothwell J; Evoy D; Geraghty J; Prichard RS
Surg Oncol; 2023 Dec; 51():102011. PubMed ID: 37931546
[TBL] [Abstract][Full Text] [Related]
30. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis.
Park S; Park JM; Cho JH; Park HS; Kim SI; Park BW
Ann Surg Oncol; 2013 Sep; 20(9):2858-65. PubMed ID: 23645483
[TBL] [Abstract][Full Text] [Related]
31. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
[TBL] [Abstract][Full Text] [Related]
32. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Liu S; Chapman JA; Burnell MJ; Levine MN; Pritchard KI; Whelan TJ; Rugo HS; Albain KS; Perez EA; Virk S; Barry G; Gao D; O'Brien P; Shepherd LE; Nielsen TO; Gelmon KA
Breast Cancer Res Treat; 2015 Jan; 149(2):439-48. PubMed ID: 25552364
[TBL] [Abstract][Full Text] [Related]
33. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
34. Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.
Carbognin L; Pilotto S; Nortilli R; Brunelli M; Nottegar A; Sperduti I; Giannarelli D; Bria E; Tortora G
Oncologist; 2016 Mar; 21(3):283-91. PubMed ID: 26865589
[TBL] [Abstract][Full Text] [Related]
35. MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy.
Wang M; Du S; Gao S; Zhao R; Liu S; Jiang W; Peng C; Chai R; Zhang L
Breast Cancer Res; 2024 Feb; 26(1):26. PubMed ID: 38347619
[TBL] [Abstract][Full Text] [Related]
36. A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors.
Pérez-Pena J; Tibor Fekete J; Páez R; Baliu-Piqué M; García-Saenz JÁ; García-Barberán V; Manzano A; Pérez-Segura P; Esparis-Ogando A; Pandiella A; Gyorffy B; Ocana A
Front Immunol; 2019; 10():2802. PubMed ID: 31921107
[TBL] [Abstract][Full Text] [Related]
37. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
Haque W; Verma V; Hatch S; Suzanne Klimberg V; Brian Butler E; Teh BS
Breast Cancer Res Treat; 2018 Aug; 170(3):559-567. PubMed ID: 29693228
[TBL] [Abstract][Full Text] [Related]
38. Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
Wang RX; Chen S; Huang L; Shao ZM
BMC Cancer; 2018 Sep; 18(1):909. PubMed ID: 30241470
[TBL] [Abstract][Full Text] [Related]
39. Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.
Prat A; Galván P; Jimenez B; Buckingham W; Jeiranian HA; Schaper C; Vidal M; Álvarez M; Díaz S; Ellis C; Nuciforo P; Ferree S; Ribelles N; Adamo B; Ramón Y Cajal S; Peg V; Alba E
Clin Cancer Res; 2016 Feb; 22(3):560-6. PubMed ID: 26152740
[TBL] [Abstract][Full Text] [Related]
40. Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
Magbanua MJM; Ahmed Z; Sayaman RW; Brown Swigart L; Hirst GL; Yau C; Wolf DM; Li W; Delson AL; Perlmutter J; Pohlmann P; Symmans WF; Yee D; Hylton NM; Esserman LJ; DeMichele AM; Rugo HS; van 't Veer LJ
Clin Cancer Res; 2024 Jun; 30(11):2444-2451. PubMed ID: 38470545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
